Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review claims


     Quick Explanation



    Author review — Christopher Liddle

    Senior, highly‑cited biomedical researcher (≈248 works, ≈21.7k citations, h≈72) with major contributions to nuclear receptor biology, metabolism, liver disease and vitamin‑D/FXR signalling — multiple high‑impact coauthored papers (Nature, Nature Medicine, Cell) show broad influence and strong collaborative role in translational endocrinology and hepatology




     Long Explanation



    Visual author review — Christopher Liddle

    Visual first: publication & citation timeline, top topics, and representative high-impact works; explanation follows.

    Representative high-impact works (coauthored)

    • PPARγ signaling and metabolism: the good, the bad and the future — Nature Medicine 2013; broad review synthesising PPARγ translational biology; Liddle is middle author and paper has high citation impact
    • Vitamin D receptor and pancreatic stromal reprogramming — Cell 2014; translational preclinical study; Liddle appears among multidisciplinary collaborators
    • REV-ERB regulation of circadian behaviour and metabolism — Nature 2012; key paper on nuclear receptor clock regulation with broad implications

    What the evidence says (concise)

    1. High productivity and impact: the OpenAlex summary reports ~248 works and ~21.7k total citations with an h-index ≈72 — consistent with a sustained, influential publication record across >30 years (see per‑year counts visualization above).
    2. Topical breadth: most work clusters in nuclear receptors, metabolism, liver disease (NASH), endocrine signalling and gene regulation — many coauthored with prominent labs (Salk Institute, Westmead, University of Sydney) indicating collaborative, translational focus .
    3. Translational emphasis: contributions include clinical/phenotypic studies (e.g., NASH and CYP biology) and mechanistic molecular studies — good balance of human and mechanistic data in coauthored outputs .

    Limitations & blindspots (critical)

    • Coauthorship vs leadership: many highly cited outputs are multi‑author; position varies (middle author on several top papers), so influence must be interpreted as collaborative rather than always PI‑led.
    • Metrics caveat: citation counts and h‑index reflect visibility and collaboration networks and can overweight review articles and large consortium works — these are useful but not sole evidence of technical novelty or unique intellectual leadership.
    • Public dataset transparency: OpenAlex provides metadata but not raw experimental data; evaluating experimental rigor requires paper‑level reading (methods, sample sizes, blinding), beyond metadata metrics alone.

    Practical takeaways & next steps

    1. Overall assessment: established, highly productive biomedical scientist with substantial collaborative contributions to nuclear receptor biology, metabolism and liver disease.
    2. To evaluate scientific rigor in detail: read representative primary research papers (methods, sample sizes, statistics, raw data availability), and audit specific experiments for reproducibility.
    3. If you want, run a focused paper‑level critique of one or two of Liddle's primary research articles (I can generate a methods/statistics checklist and flag likely weaknesses).
    Primary metadata source:

    OpenAlex author summary (author id A5049828619) provided counts_by_year, works_count=248, cited_by_count≈21754 and h_index≈72 used to build the visual timeline above.



    Feedback:    

    Updated: March 17, 2026

     BGPT Author Review



    Scientific Quality

    80%

    Sustained high productivity and influence (many coauthored high‑impact papers, substantial citation count and h‑index) indicate strong scientific competence and impact; however, many outputs are collaborative/multi‑author so individual leadership vs contribution must be assessed case‑by‑case; mechanistic/translational breadth and presence in top journals raise the score.



    Communication Quality

    80%

    Authorship on high‑visibility review and synthesis articles (Nature Medicine review, high‑impact multi‑lab papers) indicates effective scientific communication and ability to place findings in broader context; typical academic clarity and accessibility for specialist audiences.



    Author Novelty

    70%

    Work spans important, sometimes novel intersections (nuclear receptor signalling, metabolic disease, fibrosis); several coauthored primary papers present new mechanistic insights, but much of the portfolio is collaborative and synthesising rather than purely single‑lab paradigm‑shifting novelty.



    Scientific Rigor

    70%

    Overall portfolio includes mechanistic molecular biology, clinical/translational studies and large collaborations with strong methodologic standards; without paper‑level methods auditing we cannot certify uniform rigor across all works—some older clinical/translational studies may lack modern reporting/availability standards.

     Analysis Wizard



    Preparing time‑series plots and citation/works summaries from OpenAlex counts_by_year JSON to reproduce the timeline and compute yearwise citation/work rates.



     Hypothesis Graveyard



    Single‑gene causation models for NASH progression (e.g., attributing primary causation to CYP2E1 alone) are insufficient because clinical data show multi‑factorial drivers; simple single‑factor hypotheses are therefore weak.


    Assuming review article authorship equates to methodological leadership is invalid; middle authorship on high‑impact reviews often reflects contribution without full experimental leadership.

     Science Art


    Author Review: Christopher Liddle Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT